These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35262781)

  • 1. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
    Panaampon J; Kariya R; Okada S
    Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
    Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
    Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes.
    Wang YH; Hagiwara S; Kazama H; Iizuka Y; Tanaka N; Tanaka J
    J Immunol Res; 2024; 2024():1429879. PubMed ID: 38444839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
    Panaampon J; Kariya R; Okada S
    Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
    Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
    Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
    Pazina T; James AM; MacFarlane AW; Bezman NA; Henning KA; Bee C; Graziano RF; Robbins MD; Cohen AD; Campbell KS
    Oncoimmunology; 2017; 6(9):e1339853. PubMed ID: 28932638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
    Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
    Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elotuzumab for the treatment of multiple myeloma.
    Wang Y; Sanchez L; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
    van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
    Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
    Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
    Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
    Einsele H; Schreder M
    Ther Adv Hematol; 2016 Oct; 7(5):288-301. PubMed ID: 27695618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.
    Trudel S; Moreau P; Touzeau C
    Onco Targets Ther; 2019; 12():5813-5822. PubMed ID: 31410026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.
    Guo H; Cruz-Munoz ME; Wu N; Robbins M; Veillette A
    Mol Cell Biol; 2015 Jan; 35(1):41-51. PubMed ID: 25312647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
    Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
    Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Pharmacology of Elotuzumab.
    Passey C; Sheng J; Mora J; Tendolkar A; Robbins M; Dodge R; Roy A; Bello A; Gupta M
    Clin Pharmacokinet; 2018 Mar; 57(3):297-313. PubMed ID: 28779463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
    Malaer JD; Mathew PA
    Am J Cancer Res; 2017; 7(8):1637-1641. PubMed ID: 28861320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased SLAMF7
    Maekawa T; Kato S; Kawamura T; Takada K; Sone T; Ogata H; Saito K; Izumi T; Nagao S; Takano K; Okada Y; Tachi N; Teramoto M; Horiuchi T; Hikota-Saga R; Endo-Umeda K; Uno S; Osawa Y; Kobayashi A; Kobayashi S; Sato K; Hashimoto M; Suzu S; Usuki K; Morishita S; Araki M; Makishima M; Komatsu N; Kimura F
    Blood; 2019 Sep; 134(10):814-825. PubMed ID: 31270105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.